Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lymphoma 10Breast Neoplasms 8Neutropenia 7Leukemia, Myeloid, Acute 7Multiple Myeloma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Hematologic Neoplasms 4Febrile Neutropenia 4Leukemia, Monocytic, Acute 3Leukemia, Biphenotypic, Acute 3Hodgkin Disease 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Osteosarcoma 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Teratoma 1Solid Tumors 1Sarcoma, Myeloid 1Sarcoma, Clear Cell 1Rhabdoid Tumor 1Retinoblastoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1

Interventions

Cyclophosphamide 10Doxorubicin 9Vincristine 7Etoposide 7Ifosfamide 6Filgrastim 5Radiotherapy 4fludarabine phosphate 3Topotecan 3Thiotepa 3Temozolomide 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Irinotecan 3Cisplatin 3Carboplatin 3Brachytherapy 3seclidemstat 2Tacrolimus 2PM 01183 2Neoadjuvant Therapy 2Injections 2Hyperthermic Intraperitoneal Chemotherapy 2Granulocyte Colony-Stimulating Factor 2Epirubicin 2Dactinomycin 2Cytoreduction Surgical Procedures 2Cyclosporine 2Chemotherapy, Adjuvant 2thymoglobulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Desmoplastic Small Round Cell Tumor × pegylated granulocyte colony-stimulating factor × Clear all
NCT06709495 2026-02-19

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
63 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡